T-cell acute lymphoblastic leukemia (T-ALL)

T-ALL is a cancer of lymphoblasts — immature white blood cells that have stopped maturing — which were on their way to becoming T lymphocytes. T cells are the white cells that coordinate the immune system, rather than the ones that make antibodies.

It is one of the two main branches of acute lymphoblastic leukemia. The other and much larger branch is B-ALL, which comes from cells heading toward becoming antibody-making B cells. They are treated on similar backbones but the details differ, and this page is about the T-cell side.

You may see two names. T-lymphoblastic leukemia and T-lymphoblastic lymphoma are the same underlying disease presenting differently — “leukemia” when the marrow is dominant, “lymphoma” when a mass is. There is also an early T-cell precursor form, where the cells froze at a very early stage and still carry stem-cell or myeloid markers.

How common T-ALL is depends entirely on who is being counted. It is about 15% of newly diagnosed childhood ALL in one large European trial, about a quarter of all UK ALL patients across ages, and 21.7% of adults with Philadelphia-negative ALL in a large UK and US trial. Those are different denominators, not conflicting facts.

In any individual case, the cause is not known. Nothing a parent did or failed to do brings this on, and nothing the patient did either.

The disease begins with genetic changes acquired inside a single developing T cell — changes that appear during a person’s life, are not inherited, and are not passed on. The most common of them involve a signalling pathway called NOTCH: activating changes in the NOTCH1 gene occur in roughly 50% to 60% of cases, and about 60% of T-ALL has that pathway switched on through one gene or another.

Inherited susceptibility plays a small role at most. A risk variant near a gene called USP7 has been associated with T-ALL specifically, at an odds ratio of 1.44 — a modest shift in risk across a whole population, not an explanation for one person’s illness.

T-ALL is not contagious, not caused by anything in the diet, and not caused by stress or injury. The strong male predominance is well documented and is not explained; we are not going to offer a mechanism for it.

The abnormal cells fill the bone marrow and crowd out normal blood production, so most of what a person notices is a shortage: weakness and tiredness, breathlessness, pale skin, fever, infections that will not shift, easy bruising and bleeding, swollen glands, bone or joint pain, a full or painful tummy, weight loss.

The feature that most distinguishes T-ALL is a mass in the middle of the chest, and it is the thing that frightens people most. It sits in the mediastinum — the space between the lungs where the thymus gland is. The thymus is exactly where T cells normally finish maturing, which is why a T-cell leukemia so often builds a mass there.

That mass can press on the windpipe, causing breathlessness and coughing, and it can compress the large vein bringing blood back from the head and arms, so the face, neck and arms swell and go red. That last one has a name — superior vena cava obstruction — and it is treated urgently.

High white cell counts are common at diagnosis, and leukemia cells are sometimes found in the fluid around the brain and spinal cord. Symptoms usually build over days to a few weeks rather than months.

The backbone is combination chemotherapy, not a transplant, and it runs long — the NCI puts treatment of childhood ALL at two to three years, in phases, with a maintenance stretch that generally continues for two to three years of continuous remission.

Every regimen includes treatment aimed at the brain and spinal cord, because leukemia cells can shelter in the fluid there where ordinary chemotherapy reaches poorly. That means chemotherapy injected into the spinal fluid, drugs chosen to cross into the nervous system, and in some regimens radiation.

T-ALL is never treated on the gentlest protocols. The major cooperative groups exclude T-cell patients from their low and standard-risk arms as a matter of course.

Response is tracked by measurable residual disease — leukemia cells still detectable by sensitive laboratory tests after they have disappeared from view under a microscope. That measurement is the main thing driving risk grouping, and the main thing that determines whether a transplant gets discussed.

Nelarabine is the drug specific to T-cell disease. It is licensed for T-ALL and T-cell lymphoblastic lymphoma in adults and children from age one whose disease has not responded or has relapsed, and it carries a boxed warning for neurological side effects.

The start can be abrupt in a way B-ALL usually is not. Where there is a large chest mass, breathing difficulty escalates quickly and is handled as an emergency, sometimes before anyone has explained what the diagnosis is.

After that it becomes the long shape familiar from ALL generally: weeks of induction, much of it as an inpatient, a central line, repeated lumbar punctures, steroids and their particular burden of mood changes, appetite and sleeplessness, and then years of maintenance taken mostly at home.

T-ALL lands disproportionately on older children, teenagers and young adults, and that age group carries a specific weight — school and university interrupted, independence just gained and then suspended, and services that are set up either for children or for older adults rather than for them.

Follow-up continues for years after treatment ends.

For most people with T-ALL, a donor is never needed. The NCI states that a stem cell transplant is rarely used as initial treatment for children and adolescents with ALL, and is used more often for disease that comes back. EBMT marks transplant as generally not recommended for standard-risk disease with no measurable residual disease in a first remission.

A donor becomes relevant for a defined minority: people whose residual disease stays detectable, people with the early T-cell precursor form or adverse genetics, and people whose disease returns or does not respond. For those, EBMT rates transplant as standard of care.

Here is where T-ALL genuinely differs from B-ALL, and it is worth stating rather than glossing. There is no approved CAR-T product for T-lineage disease, and neither blinatumomab nor inotuzumab works here, because those drugs target markers called CD19 and CD22 that T-ALL cells do not carry. EBMT puts it plainly: salvage options in T-ALL are limited. When T-ALL relapses, a donor transplant carries relatively more of the weight than it would in B-ALL.

Teams look first for a matched brother or sister. Only a minority of people have one, and when there is not, the search moves to a matched unrelated donor or to a mismatched alternative — cord blood, or a half-matched family member. That is the point at which a volunteer registry matters.